SCM
CAPR icon

Suvretta Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Suvretta Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116M Buy
3,818,600
+2,032,990
+114% +$54.2M 2.97% 8
2025
Q4 		$51.5M Buy
+1,785,610
New +$23.3M 1.06% 36

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Suvretta Capital Management's CAPR Position: Q1 2026 in Review

Suvretta Capital Management increased its Capricor Therapeutics (CAPR) stake by 114% in Q1 2026, buying an estimated $54.2M and bringing the position to 3,818,600 shares worth $116M. The position accounts for 2.97% of the portfolio, ranked #8.

Suvretta Capital Management first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Suvretta Capital Management held 3,818,600 shares of Capricor Therapeutics worth $116M as of Q1 2026.
  • Suvretta Capital Management bought 2,032,990 Capricor Therapeutics shares in Q1 2026, an estimated $54.2M.
  • Capricor Therapeutics made up 2.97% of Suvretta Capital Management's portfolio in Q1 2026, its #8 holding.
  • Suvretta Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.